Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2022 in Advanced Malignant Tumors
NCT06131216Phase 1Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2023
- Primary completion
- Dec 2026
01
Overview
Phase 1, open-label trial of SHR-2022 in Malignant Neoplasia, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Incidence of adverse events up to 3 years, Severity of adverse events up to 3 years and 2 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
SHR-2022
03
Conditions
Malignant Neoplasia
Beyond the preview
Go deeper on NCT06131216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131216.